Skip to main content

ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis

Range Bound setup

HoldVALUE-TRAP 1/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $80.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Leverage penalty (D/E 1.1): -0.5.

ANI Pharmaceuticals is a diversified biopharmaceutical company commercializing Cortrophin Gel (Rare Disease flagship), ILUVIEN and YUTIQ (Retina Franchise acquired from Alimera in 2024), and a 120+ product Generics portfolio from three manufacturing facilities. Revenue is... Read more

$80.32+19.0% A.UpsideScore 6.4/10#3 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score8 / 9FCF yield7.78%
Stop $74.70Target $95.59(analyst − 13%)A.R:R 2.4:1
Analyst target$109.88+36.8%8 analysts
$95.59our TP
$80.32price
$109.88mean
$124

Hold if already holding. Not a fresh buy at $80.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val8.3Qual7.2Grw8.8Mom2.8Sent7.0Ins3.0Peer5.1Tech5.8Risk5.96.4OVERALL

Recent Developments — ANI Pharmaceuticals, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Risks
Concentration risk — Product: Cortrophin Gel
Leverage penalty (D/E 1.1): -0.5
Negative momentum

Key Metrics

P/E (TTM)20.3
P/E (Fwd)7.4
Mkt Cap$1.8B
EV/EBITDA10.1
Profit Mgn10.0%
ROE18.3%
Rev Growth20.5%
Beta0.46
DividendNone
Rating analysts14

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.20bullish
IV44%normal

Concentration Risks(10-K Item 1A)

  • HIGHProductCortrophin Gel
    10-K Item 1A: 'a significant portion of our net product revenues were derived from the sale of Cotrophin Gel, and we expect that sales of Cortrophin Gel will continue to account for a significant portion of our net product revenues in future years.'
  • MEDIUMSupplierone domestic API supplier17%
    10-K Item 1A: 'During the year ended December 31, 2025, approximately 17%, of our raw materials and API purchases were from one domestic supplier.'

Material Events(8-K, last 90d)

  • 2026-04-07Item 4.01HIGH
    ANI Pharmaceuticals dismissed EisnerAmper LLP as its independent registered public accounting firm effective April 1, 2026. No adverse opinions or disagreements noted. Audit Committee approved the decision.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
1.4
Rsi
4.5
Ma Position
7.2
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.6%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.8<4.5A.R:R 2.4 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
56 · Neutral
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $76.12Resistance $87.76

Price Targets

$75
$96
A.Upside+19.0%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.8/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-07 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ANIP stock a buy right now?

Hold if already holding. Not a fresh buy at $80.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Cortrophin Gel; Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $95.59 (+19.0%), stop $74.70 (−7.5%), A.R:R 2.4:1. Score 6.4/10, moderate confidence.

What is the ANIP stock price target?

Take-profit target: $95.59 (+19.0% upside). Target $95.59 (+19.0%), stop $74.70 (−7.5%), A.R:R 2.4:1. Stop-loss: $74.70.

What are the risks of investing in ANIP?

Concentration risk — Product: Cortrophin Gel; Leverage penalty (D/E 1.1): -0.5; Negative momentum.

Is ANIP overvalued or undervalued?

ANI Pharmaceuticals, Inc. trades at a P/E of 20.3 (forward 7.4). TrendMatrix value score: 8.3/10. Verdict: Hold.

What do analysts say about ANIP?

14 analysts cover ANIP with a consensus score of 4.2/5. Average price target: $110.

What does ANI Pharmaceuticals, Inc. do?ANI Pharmaceuticals is a diversified biopharmaceutical company commercializing Cortrophin Gel (Rare Disease flagship),...

ANI Pharmaceuticals is a diversified biopharmaceutical company commercializing Cortrophin Gel (Rare Disease flagship), ILUVIEN and YUTIQ (Retina Franchise acquired from Alimera in 2024), and a 120+ product Generics portfolio from three manufacturing facilities. Revenue is primarily product sales; Cortrophin Gel represented a significant portion of 2025 net product revenues.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · BHC (Bausch Health Companies Inc.) · COLL (Collegium Pharmaceutical, Inc.) · LNTH (Lantheus Holdings, Inc.)